



2-7-07

IFM

1642

Express Mail No.: EV473971339US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Richard Kim	Confirmation No.:	3898
Serial No.:	10/567,702	Art Unit:	1642
Int'l. Application Filing Date:	August 21, 2006	Examiner:	To Be Assigned
For:	ErbB RECEPTOR METHODS AND KITS FOR MONITORING CHEMOTHERAPY RESISTANCE	Attorney Docket No:	6750-189-999
		CAM No.:	305158-999187

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **C01-C44** which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." Copies of references **C01-C44** are submitted herewith.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), it is believed that no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: February 5, 2007

Samuel B. Abrams 30,605
Samuel B. Abrams (Reg. No.)

Susie S. Cheng 46,616
By: Susie S. Cheng (Reg. No.)

JONES DAY
222 East 41st Street
New York, N.Y. 10017-6702
212-326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

6750-189-999

APPLICATION NO.

10/567,702

APPLICANT

Richard Kim

U.S. FILING DATE

August 21, 2006

ART UNIT

1642

U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

	Foreign Patent Document Country Code, Number, Kind Code (If Known)	Date mm/dd/yy	Name Of Patentee Or Applicant Of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
	C01	AARANSON, 1991, "Growth factors and cancer." <i>Science</i> 254:1146-53	
	C02	BASELGA et al., 2001, "Mechanism of action of trastuzumab and scientific update." <i>Semin Oncol.</i> 28:4-11	
	C03	BASELGA, 2001, "The EGFR as a target for anticancer therapy--focus on cetuximab." <i>Eur. J. Cancer</i> 37: S16-22	
	C04	CARRAWAY & CANTLEY, "A new acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerization in growth signaling." 1994, <i>Cell</i> 78:5-8	
	C05	CIARDELLO et al., 2002, "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor." <i>Clin. Cancer Res.</i> 7:2958-70	
	C06	COUSSENS et al., 1985, "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene." <i>Science</i> 230:1132-9	
	C07	DEBONO et al., 2002, "The ErbB receptor family: a therapeutic target for cancer" <i>Trends in Mol. Med.</i> 8(4): S19-S26	
	C08	FALLS, 2003, "Neuregulins: functions, forms, and signaling strategies." <i>Exp. Cell. Res.</i> 284(1): 14-30	
	C09	FAN et al., 1994, <i>J. Biol. Chem.</i> 269:27585-602	
	C10	GENBANK Accession No. AH001455, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 1"	
	C11	GENBANK Accession No. AY207002, "Homo sapiens neuregulin 1 isoform 4 (NRG1) mRNA, partial cds, alternatively spliced."	
	C12	GENBANK Accession No. NM-004883, "Homo sapiens neuregulin 2 (NRG2), transcript variant 1, mRNA."	
	C13	GENBANK Accession No. NM-013981, "Homo sapiens neuregulin 2 (NRG2), transcript variant 2, mRNA."	
	C14	GENBANK Accession No. NM-013982, "Homo sapiens neuregulin 2 (NRG2), transcript variant 3, mRNA."	
	C15	GENBANK Accession No. NM-013983, "Homo sapiens neuregulin 2 (NRG2), transcript variant 4, mRNA."	
	C16	GENBANK Accession No. NM-013984, "Homo sapiens neuregulin 2 (NRG2), transcript variant 5, mRNA"	
	C17	GENBANK Accession No. NM-013985, "Homo sapiens neuregulin 2 (NRG2), transcript variant 6, mRNA."	
	C18	GENBANK Accession No. NM-031507, "Rattus norvegicus epidermal growth factor receptor (Egfr), mRNA."	

EXAMINER

NYI-3927254v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

6750-189-999

APPLICATION NO.

10/567,702

APPLICANT

Richard Kim

U.S. FILING DATE

August 21, 2006

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
	C19	GENBANK Accession No.: AF041792, "Gallus gallus tyrosine kinase ERBB-4 (ERBB4) mRNA, partial cds."	
	C20	GENBANK Accession No.: M11762, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 2."	
	C21	GENBANK Accession No.: M11763, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 3."	
	C22	GENBANK Accession No.: M11764, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 4."	
	C23	GENBANK Accession No.: M11765, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 5."	
	C24	GENBANK Accession No.: M11766, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 6."	
	C25	GENBANK Accession No.: M11767, "Homo sapiens protooncogene protein (c-erb-2) gene, exon 7 and partial cds."	
	C26	GOLDSTEIN et al., 1995, "Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model." <i>Clin. Cancer. Res.</i> 1:1311-8	
	C27	GOUSTIN et al, 1986, "Growth factors and cancer." <i>Cancer Res</i> 46: 1015-29	
	C28	HANCOCK et al., 1991, "A monoclonal antibody against the c-ErbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines." <i>Cancer Res.</i> 51:4575-80	
	C29	LOGAN & SHENK, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection." <i>Proc. Natl. Acad. Sci USA</i> 81:3655	
	C30	NOONBERG et al., 2000, "Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents." <i>Drugs</i> 59:753-67	
	C31	OLAYIOYE et al., 2000, "The ErbB signaling network: receptor heterodimerization in development and cancer." <i>EMBO J.</i> 19:3159-67	
	C32	PLOWMAN et al., 1990, "Molecular cloning and expression of an additional epidermal growth factor receptor-related gene." <i>Proc. Natl. Acad. Sci USA</i> 87:4905-9	
	C33	PLOWMAN et al., 1993, "Ligand-specific activation of HER4/p180 ^{erbB4} , a fourth member of the epidermal growth factor receptor family." <i>Proc. Natl. Acad. Sci USA</i> 90:1746-50	
	C34	PREWETT et al., 1996, "The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma." <i>J. Immunother. Tumor. Immunol.</i> 19: 419-427	
	C35	SAMPSON et al., 2000, "Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors." <i>Proc. Natl. Acad. Sci. USA</i> 97:7503-8	
	C36	SCHLESSINGER, 2000, "Cell signaling by receptor tyrosine kinases." <i>Cell</i> 103:211-225	
	C37	SEDLACEK, 2000, "Kinase inhibitors in cancer therapy: a look ahead." <i>Drugs</i> 59:435-76	
	C38	SIMON, 2000, "Receptor Tyrosine Kinases: Specific Outcomes from General Signals" <i>Cell</i> 103:13-15	
	C39	TANG C.K. & LIPPMAN, M.E. in <u>Hormones and Signaling</u> , ed. O'Malley, B.W., 113-165, Academic Press, San Diego	
	C40	ULRICH et al., 1984, "Search for selectivity in interactions of chiral solvated electrons." <i>Nature</i> 309:418-425	
	C41	WELLS, 1999, "EGF receptor" <i>Int. J. Biochem & Cell Biol.</i> 31:637-43	
	C42	WOODBURN, 1999, "The epidermal growth factor receptor and its inhibition in cancer therapy." <i>Pharmacol. Ther.</i> 82:241-50	

EXAMINER

NYI-3927254v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Express Mail No.: EV473971339US

Sheet 3 of 3

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

6750-189-999

APPLICATION NO.

10/567,702

APPLICANT

Richard Kim

U.S. FILING DATE

August 21, 2006

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published)	T
	C43	YANG et al., 2000, "Therapeutic Potential of ABX-EGF, a Fully Human Anti-EGF Receptor Monoclonal Antibody, for Cancer Treatment." <i>Proc. Am. Soc. Clin. Oncol.</i> 19:48	
	C44	ZHANG et al., 1997, "Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4." <i>Proc. Natl. Acad Sci USA</i> 94: 9562-7	

EXAMINER

NYI-3927254v1

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.